{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T06:07:00Z","timestamp":1789020420083,"version":"build-2803163510"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Leptin is an adipokine involved in metabolic regulation and neurohormonal activation and has been implicated in the pathophysiology of heart failure. Sacubitril\/valsartan (angiotensin receptor\u2013neprilysin inhibitor, ARNI) improves outcomes in patients with heart failure with reduced ejection fraction (HFrEF) and may also influence metabolic pathways. However, it remains unclear whether ARNI therapy affects circulating leptin levels differently in men and women.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this observational study, patients with HFrEF from two clinical centres were evaluated before and after initiation of sacubitril\/valsartan therapy. Serum leptin levels, N-terminal pro-B-type Natriuretic Peptide (NT-proBNP), echocardiographic parameters and New York Heart Association (NYHA) class were assessed at baseline and follow-up. Sex-specific differences in leptin levels and leptin dynamics were analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 74 patients (20 women and 54 men) were included. Women exhibited significantly higher leptin levels compared with men at baseline (39.78\u2009\u00b1\u200931.95 vs. 10.39\u2009\u00b1\u200917.04\u2005ng\/mL,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001) despite similar body mass index (BMI) values (ns). Following initiation of ARNI therapy, leptin levels increased significantly in both women (39.78\u2009\u00b1\u200931.95 to 50.10\u2009\u00b1\u200941.28,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.041) and men (10.39\u2009\u00b1\u200917.04 to 12.49\u2009\u00b1\u200916.62,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006). However, the magnitude of absolute and relative leptin change did not differ significantly between sexes. Improvements in left ventricular ejection fraction (LVEF) were observed in both groups, while changes in NT-proBNP and NYHA class showed different within-group patterns but did not differ significantly between sexes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Women with HFrEF showed markedly higher circulating leptin levels than men at both baseline and follow-up. Leptin levels increased significantly in both sexes. However, there were no significant differences in absolute or relative leptin changes between women and men. Sex influences baseline leptin concentrations, but not the response to ARNI therapy. Further prospective studies are needed to clarify the mechanisms and clinical significance of leptin changes during sacubitril\/valsartan treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1922853","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:33:08Z","timestamp":1789018388000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Sex differences in leptin levels but not in the leptin response to sacubitril\/valsartan in patients with heart failure with reduced ejection fraction"],"prefix":"10.3389","volume":"13","author":[{"given":"Zornitsa","family":"Shomanova","sequence":"first","affiliation":[{"name":"Interdisciplinary Heart Failure Section, University Hospital M\u00fcnster","place":["M\u00fcnster, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Ohnewein","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Paracelsus Medical University","place":["Salzburg, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilvin","family":"Semo","sequence":"additional","affiliation":[{"name":"Department of Cardiology I, Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital M\u00fcnster","place":["M\u00fcnster, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Paar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Paracelsus Medical University","place":["Salzburg, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Fr\u00f6hling","sequence":"additional","affiliation":[{"name":"Department of Cardiology I, Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital M\u00fcnster","place":["M\u00fcnster, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen R.","family":"Sindermann","sequence":"additional","affiliation":[{"name":"Interdisciplinary Heart Failure Section, University Hospital M\u00fcnster","place":["M\u00fcnster, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta C.","family":"Hoppe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Paracelsus Medical University","place":["Salzburg, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lichtenauer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Paracelsus Medical University","place":["Salzburg, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Zechowicz","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Internal Medicine, School of Medicine, Collegium Medicum, University of Warmia and Mazury","place":["Olsztyn, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas J.","family":"Motloch","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Paracelsus Medical University","place":["Salzburg, Austria"]},{"name":"Department of Cardiology, Kepler University Hospital, Johannes Kepler University","place":["Linz, Austria"]},{"name":"Department of Internal Medicine II, Salzkammergut Klinikum, O\u00d6G","place":["V\u00f6cklabruck, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudin","family":"Pistulli","sequence":"additional","affiliation":[{"name":"Department of Cardiology I, Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital M\u00fcnster","place":["M\u00fcnster, Germany"]},{"name":"Medical Clinic I, Marienhospital Papenburg Aschendorf GGmbH","place":["Papenburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrcardio.2016.163","article-title":"Neurohormonal activation in heart failure with reduced ejection fraction","volume":"14","author":"Hartupee","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1177\/2040622316665350","article-title":"Sacubitril\/valsartan in heart failure: latest evidence and place in therapy","volume":"7","author":"Kaplinsky","year":"2016","journal-title":"Ther Adv Chronic Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1136\/heartjnl-2014-306775","article-title":"The neprilysin pathway in heart failure: a review and guide on the use of sacubitril\/valsartan","volume":"102","author":"Jhund","year":"2016","journal-title":"Heart"},{"key":"B4","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/cpt.455","article-title":"Improved insulin sensitivity with angiotensin receptor neprilysin inhibition in individuals with obesity and hypertension","volume":"101","author":"Jordan","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1038\/s41598-018-22194-z","article-title":"The effects of angiotensin receptor neprilysin inhibition by sacubitril\/valsartan on adipose tissue transcriptome and protein expression in obese hypertensive patients","volume":"8","author":"Stinkens","year":"2018","journal-title":"Sci Rep"},{"key":"B7","doi-asserted-by":"publisher","first-page":"R642","DOI":"10.1152\/ajpregu.00133.2007","article-title":"Leptin, skeletal muscle lipids, and lipid-induced insulin resistance","volume":"293","author":"Dube","year":"2007","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1139\/cjpp-2013-0057","article-title":"The potential contribution of circulating and locally produced leptin to cardiac hypertrophy and failure","volume":"91","author":"Karmazyn","year":"2013","journal-title":"Can J Physiol Pharmacol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1093\/cvr\/cvm023","article-title":"Leptin signalling reduces the severity of cardiac dysfunction and remodelling after chronic ischaemic injury","volume":"77","author":"McGaffin","year":"2008","journal-title":"Cardiovasc Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11906-013-0356-1","article-title":"The sympathetic nervous system in obesity hypertension","volume":"15","author":"Lohmeier","year":"2013","journal-title":"Curr Hypertens Rep"},{"key":"B11","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3389\/fnins.2014.00232","article-title":"Leptin into the rostral ventral lateral medulla (RVLM) augments renal sympathetic nerve activity and blood pressure","volume":"8","author":"Barnes","year":"2014","journal-title":"Front Neurosci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1161\/HYPERTENSIONAHA.115.06736","article-title":"Leptin mediates high-fat diet sensitization of angiotensin II-elicited hypertension by upregulating the brain renin-angiotensin system and inflammation","volume":"67","author":"Xue","year":"2016","journal-title":"Hypertension"},{"key":"B13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/MNH.0000000000000384","article-title":"The regulation of aldosterone secretion by leptin","volume":"27","author":"Faulkner","year":"2018","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B14","doi-asserted-by":"publisher","first-page":"F7","DOI":"10.1530\/JOE-16-0160","article-title":"Obesity, hypertension and aldosterone: is leptin the link?","volume":"230","author":"Xie","year":"2016","journal-title":"J Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1093\/eurjhf\/hfs111","article-title":"High leptin and resistin expression in chronic heart failure: adverse outcome in patients with dilated and inflammatory cardiomyopathy","volume":"14","author":"Bobbert","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.cardfail.2011.08.010","article-title":"Dynamics in insulin resistance and plasma levels of adipokines in patients with acute decompensated and chronic stable heart failure","volume":"17","author":"Schulze","year":"2011","journal-title":"J Card Fail"},{"key":"B17","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1161\/CIRCHEARTFAILURE.111.964031","article-title":"Adipose tissue inflammation and adiponectin resistance in patients with advanced heart failure","volume":"5","author":"Khan","year":"2012","journal-title":"Circ Heart Fail"},{"key":"B18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1388-9842(02)00177-0","article-title":"Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure","volume":"5","author":"Schulze","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"B19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5603\/EP.2017.0005","article-title":"The effect of BMI, serum leptin, and adiponectin levels on prognosis in patients with non-ischaemic dilated cardiomyopathy","volume":"68","author":"Wojciechowska","year":"2017","journal-title":"Endokrynol Pol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1053\/euhj.1998.1045","article-title":"Hyperleptinaemia in chronic heart failure relationships with insulin","volume":"19","author":"Leyva","year":"1998","journal-title":"Eur Heart J"},{"key":"B21","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0167-5273(02)00022-0","article-title":"Insulin resistance in moderate chronic heart failure is related to hyperleptinaemia, but not to norepinephrine or TNF-alpha","volume":"83","author":"Doehner","year":"2002","journal-title":"Int J Cardiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"8232","DOI":"10.1038\/s41598-017-07473-5","article-title":"Sex steroid hormones regulate leptin transcript accumulation and protein secretion in 3T3-L1 cells","volume":"7","author":"Jenks","year":"2017","journal-title":"Sci Rep"},{"key":"B23","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1210\/jcem.82.2.3739","article-title":"Sexual dimorphism in plasma leptin concentration","volume":"82","author":"Saad","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.phrs.2006.11.001","article-title":"Gender differences in drug responses","volume":"55","author":"Franconi","year":"2007","journal-title":"Pharmacol Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10557-015-6611-8","article-title":"Gender differences in cardiovascular drugs","volume":"29","author":"Stolarz","year":"2015","journal-title":"Cardiovasc Drugs Ther"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1007\/s001250050804","article-title":"Plasma leptin concentrations: gender differences and associations with metabolic risk factors for cardiovascular disease","volume":"40","author":"Couillard","year":"1997","journal-title":"Diabetologia"},{"key":"B27","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1046\/j.1365-2796.2000.00678.x","article-title":"Mechanisms behind gender differences in circulating leptin levels","volume":"247","author":"Hellstr\u00f6m","year":"2000","journal-title":"J Intern Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e3466","DOI":"10.1371\/journal.pone.0003466","article-title":"Gender dimorphism in skeletal muscle leptin receptors, serum leptin and insulin sensitivity","volume":"3","author":"Guerra","year":"2008","journal-title":"PLoS One"},{"key":"B29","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1159\/000145018","article-title":"Dynamic responses to leptin secretagogues in lean, obese, and massively obese men and women","volume":"70","author":"Dagogo-Jack","year":"2008","journal-title":"Horm Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1210\/endo-126-2-1229","article-title":"The effects of androgens on the regulation of lipolysis in adipose precursor cells","volume":"126","author":"Xu","year":"1990","journal-title":"Endocrinology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1172\/JCI119595","article-title":"Contribution of androgens to the gender difference in leptin production in obese children and adolescents","volume":"100","author":"Wabitsch","year":"1997","journal-title":"J Clin Invest"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1210\/endo.140.4.6617","article-title":"In vivo and in vitro ob gene expression and leptin secretion in rat adipocytes: evidence for a regional specific regulation by sex steroid hormones","volume":"140","author":"Machinal","year":"1999","journal-title":"Endocrinology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1210\/jcem.82.4.3859","article-title":"The metabolic significance of leptin in humans: gender-based differences in relationship to adiposity, insulin sensitivity, and energy expenditure","volume":"82","author":"Kennedy","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"B34","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jchf.2020.06.020","article-title":"Sacubitril\/valsartan","volume":"8","author":"Docherty","year":"2020","journal-title":"JACC Heart Fail"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1038\/ijo.2010.227","article-title":"Neprilysin, obesity and the metabolic syndrome","volume":"35","author":"Standeven","year":"2011","journal-title":"Int J Obes (Lond)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11010-017-2948-6","article-title":"Neprilysin facilitates adipogenesis through potentiation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway","volume":"430","author":"Kim","year":"2017","journal-title":"Mol Cell Biochem"},{"key":"B37","doi-asserted-by":"publisher","first-page":"48066","DOI":"10.1074\/jbc.M204058200","article-title":"Human adipose tissue cells keep tight control on the angiotensin II levels in their vicinity","volume":"277","author":"Schling","year":"2002","journal-title":"J Biol Chem"},{"key":"B38","doi-asserted-by":"publisher","first-page":"612","DOI":"10.2337\/dc08-1596","article-title":"Plasma leptin levels and incidence of heart failure, cardiovascular disease, and total mortality in elderly individuals","volume":"32","author":"Lieb","year":"2009","journal-title":"Diabetes Care"},{"key":"B39","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s10741-025-10501-6","article-title":"Leptin and heart failure: the chicken or the egg?","volume":"30","author":"Theodorakis","year":"2025","journal-title":"Heart Fail Rev"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1016\/j.numecd.2022.06.006","article-title":"High leptin status indicates an increased risk of mortality and heart failure in stable coronary artery disease","volume":"32","author":"Mayer","year":"2022","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"B41","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1517\/17530059.2013.735229","article-title":"Leptin in heart failure","volume":"7","author":"Barbosa-Ferreira","year":"2013","journal-title":"Expert Opin Med Diagn"},{"key":"B42","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.3390\/ijms22105187","article-title":"Autonomic nervous system in obesity and insulin-resistance\u2014the Complex interplay between leptin and central nervous system","volume":"22","author":"Russo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B43","doi-asserted-by":"publisher","first-page":"R566","DOI":"10.1152\/ajpregu.00180.2013","article-title":"Selective leptin resistance revisited","volume":"305","author":"Mark","year":"2013","journal-title":"Am. J. Physiol. Regul. Integr. Compar. Physiol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1096\/fj.02-0158rev","article-title":"Analysis of paradoxical observations on the association between leptin and insulin resistance","volume":"16","author":"Ceddia","year":"2002","journal-title":"FASEB J"},{"key":"B45","doi-asserted-by":"publisher","first-page":"108877","DOI":"10.1016\/j.neuropharm.2021.108877","article-title":"Peripheral versus central insulin and leptin resistance: role in metabolic disorders, cognition, and neuropsychiatric diseases","volume":"203","author":"Erichsen","year":"2022","journal-title":"Neuropharmacology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e019712","DOI":"10.1161\/JAHA.120.019712","article-title":"Differences in NT-proBNP response and prognosis in men and women with heart failure with reduced ejection fraction","volume":"10","author":"Daubert","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e028865","DOI":"10.1161\/JAHA.122.028865","article-title":"Sex differences in the effectiveness of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and sacubitril\u2013valsartan for the treatment of heart failure","volume":"12","author":"Sohani","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e009629","DOI":"10.1161\/CIRCHEARTFAILURE.122.009629","article-title":"Proteomic biomarkers of sacubitril\/valsartan treatment response in heart failure with preserved ejection fraction: molecular insights into sex differences","volume":"15","author":"Nguyen","year":"2022","journal-title":"Circ Heart Fail"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1002\/ejhf.2005","article-title":"Sex-based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril\/valsartan","volume":"22","author":"Ibrahim","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B50","doi-asserted-by":"publisher","first-page":"5940","DOI":"10.1038\/s41598-021-85490-1","article-title":"The influence of sex and body mass index on the association between soluble neprilysin and risk of heart failure hospitalizations","volume":"11","author":"N\u00fa\u00f1ez","year":"2021","journal-title":"Sci Rep"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/ehf2.14260","article-title":"Psychosocial factors partially explain gender differences in health-related quality of life in heart failure patients","volume":"10","author":"Tapia","year":"2023","journal-title":"ESC Heart Fail"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1922853\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:33:08Z","timestamp":1789018388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1922853\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":51,"alternative-id":["10.3389\/fcvm.2026.1922853"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1922853","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"article-number":"1922853"}}